Mustang Bio, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2025

Note 6 - Accounts Payable and Accrued Expenses

At December 31, 2025 and 2024, accounts payable and accrued expenses consisted of the following:


	December 31,
($ in thousands)	2025		2024
Accounts payable	$	3,510	$	7,464
Accrued research and development		250		330
Accrued compensation		24		93
Other⁽¹⁾		1,627		1,599
Total accounts payable and accrued expenses	$	5,411	$	9,486

⁽¹⁾ Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 4.